High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium.

Poor vitamin D status is associated with a higher relapse rate and earlier disability in multiple sclerosis. Based on these associations, patients with multiple sclerosis are frequently supplemented with the vitamin D precursor cholecalciferol, although it is unclear whether this regimen is of therapeutic benefit. To model consequences of this common practice, mice were fed for more than 3 months with a low, medium or high dose of cholecalciferol, representative of vitamin D deficiency, modest and disproportionally high supplementation, respectively, in patients with multiple sclerosis. Compared to vitamin D-deprived mice, its moderate supplementation reduced the severity of subsequent experimental autoimmune encephalomyelitis, which was associated with an expansion of regulatory T cells. Direct exposure of murine or human T cells to vitamin D metabolites inhibited their activation. In contrast, mice with 25-(OH) vitamin D levels above 200 nmol/l developed fulminant experimental autoimmune encephalomyelitis with massive CNS infiltration of activated myeloid cells, Th1 and Th17 cells. When dissecting this unexpected outcome, we observed that high, but not medium dose vitamin D had caused mild hypercalcaemia, which rendered T cells more prone to pro-inflammatory activation. Exposing murine or human T cells to equivalent calcium concentrations in vitro enhanced its influx, triggering activation, upregulation of pro-inflammatory gene products and enhanced transmigration across a blood-brain barrier model. These findings suggest that vitamin D at moderate levels may exert a direct regulatory effect, while continuous high dose vitamin D treatment could trigger multiple sclerosis disease activity by raising mean levels of T-cell excitatory calcium.

[1]  Jorge R. Oksenberg,et al.  The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. , 2017, Trends in genetics : TIG.

[2]  T. Jin,et al.  1,25‐dihydroxyvitamin D3‐induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells , 2017, Immunology.

[3]  S. Feske,et al.  Store‐Operated Ca2+ Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming , 2017, Immunity.

[4]  P. Bhargava,et al.  Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. , 2017, JCI insight.

[5]  F. Barkhof,et al.  High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon β-1a (scIFNβ-1a) (S44.005) , 2017 .

[6]  J. Hell,et al.  Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis , 2017, Proceedings of the National Academy of Sciences.

[7]  D. Hougaard,et al.  Neonatal vitamin D status and risk of multiple sclerosis , 2017, Neurology.

[8]  J. Damoiseaux,et al.  Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study , 2016, Journal of Neuroimmunology.

[9]  H. Bading,et al.  Nuclear calcium is required for human T cell activation , 2016, The Journal of cell biology.

[10]  C. Lawes,et al.  Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. , 2016, The American journal of clinical nutrition.

[11]  A. Hanff,et al.  Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men , 2016 .

[12]  W. Brück,et al.  Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen , 2016, Acta Neuropathologica.

[13]  P. Bhargava,et al.  Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis , 2016, Neurology.

[14]  H. Søndergaard,et al.  Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis , 2015, Multiple sclerosis.

[15]  M. Behmanesh,et al.  Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients. , 2015, International immunopharmacology.

[16]  C. Greenwood,et al.  Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study , 2015, PLoS medicine.

[17]  T. Yednock,et al.  Melanoma cell adhesion molecule–positive CD8 T lymphocytes mediate central nervous system inflammation , 2015, Annals of neurology.

[18]  S. Nessler,et al.  Vitamin D deficiency decreases survival of bacterial meningoencephalitis in mice , 2015, Journal of Neuroinflammation.

[19]  J. Wetterslev,et al.  Vitamin D supplementation for prevention of mortality in adults. , 2014, The Cochrane database of systematic reviews.

[20]  A. Damasceno,et al.  Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D , 2014, Journal of the Neurological Sciences.

[21]  P. Bhargava,et al.  The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. , 2014, Contemporary clinical trials.

[22]  E. Granieri,et al.  Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study , 2014, Multiple sclerosis.

[23]  Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) , 2013, Inflammation Research.

[24]  G. Cutter,et al.  Disability in multiple sclerosis , 2013, Neurology.

[25]  T. Sparwasser,et al.  1,25-dihydroxyvitamin D exerts similar immunosuppressive effects as UVR but is dispensable for local UVR-induced immunosuppression. , 2012, The Journal of investigative dermatology.

[26]  C. Mathieu,et al.  1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. , 2012, Immunobiology.

[27]  T. Yednock,et al.  Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system. , 2012, Brain : a journal of neurology.

[28]  A. Ponsonby,et al.  Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS , 2012, Neurology.

[29]  T. Holmøy,et al.  Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment , 2012, Neurology.

[30]  W. Hop,et al.  Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis , 2012, Neurology.

[31]  M. Filippi,et al.  A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  F. Paul,et al.  Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial , 2012, Trials.

[33]  D. Goodin,et al.  Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. , 2012, Archives of neurology.

[34]  D. Wingerchuk Smoking: effects on multiple sclerosis susceptibility and disease progression , 2012, Therapeutic advances in neurological disorders.

[35]  B. Baaten,et al.  Regulation of Antigen-Experienced T Cells: Lessons from the Quintessential Memory Marker CD44 , 2011, Front. Immun..

[36]  M. Stein,et al.  A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis , 2011, Neurology.

[37]  H. Rieger,et al.  Calcium microdomains at the immunological synapse: how ORAI channels, mitochondria and calcium pumps generate local calcium signals for efficient T‐cell activation , 2011, The EMBO journal.

[38]  J. Damoiseaux,et al.  Effects of vitamin D on the peripheral adaptive immune system: a review. , 2011, Autoimmunity reviews.

[39]  C. Mayne,et al.  1,25‐Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis , 2011, European journal of immunology.

[40]  P. Menheere,et al.  Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis , 2010, PloS one.

[41]  S. Feske,et al.  T‐cell‐specific deletion of STIM1 and STIM2 protects mice from EAE by impairing the effector functions of Th1 and Th17 cells , 2010, European journal of immunology.

[42]  J. M. Burton,et al.  A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis , 2010, Neurology.

[43]  A. Ascherio,et al.  Vitamin D and multiple sclerosis , 2010, The Lancet Neurology.

[44]  A. Ascherio,et al.  Epstein–Barr Virus Infection and Multiple Sclerosis: A Review , 2010, Journal of Neuroimmune Pharmacology.

[45]  H. DeLuca,et al.  Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin , 2009, Proceedings of the National Academy of Sciences.

[46]  M. Holick,et al.  Vitamin D status: measurement, interpretation, and clinical application. , 2009, Annals of epidemiology.

[47]  J. Kinet,et al.  Calcium signaling in immune cells , 2008, Nature Immunology.

[48]  A. Kessels,et al.  Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis , 2008, Multiple sclerosis.

[49]  C. Carlberg,et al.  The vitamin D receptor. , 2007, Dermatologic clinics.

[50]  S. Feske Calcium signalling in lymphocyte activation and disease , 2007, Nature Reviews Immunology.

[51]  P. Lipsky,et al.  Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation , 2007, The Journal of Immunology.

[52]  Y. Gwack,et al.  Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes. , 2007, Cell calcium.

[53]  M. Holick Vitamin D deficiency. , 2007, The New England journal of medicine.

[54]  A. Ascherio,et al.  Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors , 2007, Annals of neurology.

[55]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[56]  P. Duquette,et al.  Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis , 2006, Annals of neurology.

[57]  K. Spach,et al.  Vitamin D3 Confers Protection from Autoimmune Encephalomyelitis Only in Female Mice1 , 2005, The Journal of Immunology.

[58]  G. Rice,et al.  A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[60]  Yan Zhu,et al.  Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. , 2004, The American journal of clinical nutrition.

[61]  M. Holick Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. , 2004, The American journal of clinical nutrition.

[62]  S. Khoury,et al.  Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.

[63]  T. Meehan,et al.  The vitamin D receptor is necessary for 1α,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice ☆ , 2002 .

[64]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[65]  Richard S Lewis,et al.  Calcium signaling mechanisms in T lymphocytes. , 2001, Annual review of immunology.

[66]  H. DeLuca,et al.  Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. , 2000, Archives of biochemistry and biophysics.

[67]  F. Nashold,et al.  1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[68]  R. Vieth,et al.  Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. , 1999, The American journal of clinical nutrition.

[69]  Keli Xu,et al.  Calcium oscillations increase the efficiency and specificity of gene expression , 1998, Nature.

[70]  T. Jansen,et al.  Severe hypercalcaemia syndrome with daily low-dose vitamin D supplementation. , 1997, British journal of rheumatology.

[71]  H. DeLuca,et al.  1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[72]  J. Herbert,et al.  High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis , 1994, Neurology.

[73]  K. Miyazono,et al.  A role of the latent TGF‐beta 1‐binding protein in the assembly and secretion of TGF‐beta 1. , 1991, The EMBO journal.

[74]  J. Lemire,et al.  1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.

[75]  M. Holick Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. , 1987, Federation proceedings.

[76]  M. Kuno,et al.  Ion channels activated by inositol 1,4,5-trisphosphate in plasma membrane of human T-lymphocytes , 1987, Nature.

[77]  S. Manolagas,et al.  1 alpha,25-Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. , 1986, Journal of immunology.

[78]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[79]  E. Acheson,et al.  SOME COMMENTS ON THE RELATIONSHIP OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS TO LATITUDE, SOLAR RADIATION, AND OTHER VARIABLES , 1960, Acta psychiatrica Scandinavica. Supplementum.